Clinical Trial Detail

NCT ID NCT02657434
Title A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-squamous non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Atezolizumab + Carboplatin + Pemetrexed Disodium

Atezolizumab + Cisplatin + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST